Analyzing Kezar Life Sciences (NASDAQ:KZR) and Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ:ENLV) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares Enlivex Therapeutics and Kezar Life Sciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	-$29.07 million	($0.73)	-1.18
Kezar Life Sciences	$7.00 million	4.34	-$101.87 million	($11.55)	-0.36

Enlivex Therapeutics has higher earnings, but lower revenue than Kezar Life Sciences. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Enlivex Therapeutics and Kezar Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	-67.57%	-58.45%
Kezar Life Sciences	N/A	-54.95%	-46.11%

Volatility & Risk

Enlivex Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Enlivex Therapeutics and Kezar Life Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	0	0	2	1	3.33
Kezar Life Sciences	0	2	1	0	2.33

Enlivex Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 1,056.07%. Kezar Life Sciences has a consensus price target of $39.50, indicating a potential upside of 849.52%. Given Enlivex Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Kezar Life Sciences.

Summary

Enlivex Therapeutics beats Kezar Life Sciences on 8 of the 13 factors compared between the two stocks.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

About Kezar Life Sciences

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.